Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ER negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ER negative	Breast Cancer	ER negative	Breast Cancer	toremifene Resistant: A1 - Approval toremifene Resistant : A1	toremifene Resistant: A1 - Approval toremifene Resistant : A1
ER negative	Breast Cancer	ER negative	Breast Cancer	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1	anastrozole Sensitive: A1 - Approval anastrozole Sensitive : A1
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	pertuzumab + trastuzumab-pkrb Sensitive: C3 – Early Trials pertuzumab + trastuzumab-pkrb Sensitive : C3	pertuzumab + trastuzumab-pkrb Sensitive: C3 – Early Trials pertuzumab + trastuzumab-pkrb Sensitive : C3
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
ER negative	Breast Cancer	ER negative	Breast Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
ER negative	Breast Cancer	ER negative	Breast Cancer	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	HER2 inhibitor Sensitive: C3 – Early Trials HER2 inhibitor Sensitive : C3	HER2 inhibitor Sensitive: C3 – Early Trials HER2 inhibitor Sensitive : C3
ER negative	HER2 Negative Breast Cancer	ER negative	HER2 Negative Breast Cancer	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D
ER negative	HER2 Negative Breast Cancer	ER negative	HER2 Negative Breast Cancer	docetaxel Resistant: D – Preclinical docetaxel Resistant : D	docetaxel Resistant: D – Preclinical docetaxel Resistant : D
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D	doxorubicin hydrochloride Resistant: D – Preclinical doxorubicin hydrochloride Resistant : D
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	docetaxel Resistant: D – Preclinical docetaxel Resistant : D	docetaxel Resistant: D – Preclinical docetaxel Resistant : D